Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Johnson's concerns &. Settlement agreement

12. I am particulary concerned by two licenses written by TPL in the first quarter of 2010 that appear substantially low in relation to the gross sales reported by those companies. The amounts of the licenses appear to be below the licensing criteria that we have agreed to with TPL under the Business Plan of the ComAg.

Now look at this from the ComAg

6.2 P-Newco may terminate this Commercialization Agreement if:

(a) TPL has failed to close transactions in accordance with

the Performance Milestones set forth in Section IV of Schedule 2, and

Doesn’t it appear that based on Johnson’s concerns in above, this may have been grounds to terminate the ComAg. Hopefully, the terms of the settlement agreement will tell us more.

Share
New Message
Please login to post a reply